Search filters

List of works by Mario Tiribelli

"Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay." Is dPCR the key?

scientific article published on 07 July 2019

ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML.

scientific article published on 15 June 2017

ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia

scientific article

ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome

scientific article published on 9 June 2015

ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission

scientific article

Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma

scientific article

Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells

scientific article published on 01 November 2005

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

scientific article

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases

scientific article

BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.

scientific article published on 23 July 2013

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

scientific article published on 27 June 2017

Biological and clinical features of T-biphenotypic acute leukaemia: report from a single centre

scientific article published on 01 June 2004

Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy

scientific article

Cardiotoxicity of imatinib: At the heart of the problem

scientific article published on 01 January 2011

Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients

scientific article published on 01 January 2007

Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.

scientific article published in September 2005

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey

scientific article published on 18 June 2020

Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera

scientific article published on 20 November 2014

Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.

scientific article published on 18 August 2015

Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.

scientific article

Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells

scientific article published on 12 November 2007

Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse

scientific article published on 29 November 2010

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

article by Simona Soverini et al published 15 December 2006 in Clinical Cancer Research

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy

scientific article

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

scientific article published on 25 June 2011

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

scientific article published on 30 October 2014

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar

scientific article published on 05 June 2018

Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70

article

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

scientific article published on 04 April 2019

Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

article

Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia ⬇️

scientific article published on August 15, 2012

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

scholarly article by Francesca Palandri et al published November 2018 in Leukemia Research

EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations

scientific article published on 29 November 2013

EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia

scientific article published on 11 August 2013

Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells.

scientific article published on 5 July 2005

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

scientific article

Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy

scientific article published on 16 September 2019

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

scientific article published on 14 June 2019

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study

scientific article

Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia

scientific article published in May 2002

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients

scientific article published on 6 April 2018

Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia.

scientific article published in May 2006

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

scientific article

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.

scientific article

FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience

scientific article published in October 2009

Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy

scientific article published on 19 June 2014

Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients

scientific article

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome

scientific article published on 26 March 2008

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

scientific article published on September 2016

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

article by Gabriele Gugliotta et al published 26 May 2011 in Blood

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

scientific article published on 26 January 2006

Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology

scientific article published on 01 June 2015

Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology.

scientific article published on 8 July 2013

Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years

scientific article published on 14 July 2008

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib

scientific article published on 2 March 2018

Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

scientific article published on 02 September 2019

High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients

scientific article

Histone post-translational modifications associated to BAALC expression in leukemic cells

scientific article

How could patient reported outcomes improve patient management in chronic myeloid leukemia?

scientific article

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

scientific article published on 27 August 2016

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

scientific article published in August 2013

Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias

scientific article

Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis

scientific article published on 08 January 2007

Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response ⬇️

scientific article published on 27 March 2015

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

scientific article published on 07 June 2019

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

scientific article published on 10 October 2012

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

scientific article published on 04 December 2018

Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia.

scientific article published on 11 January 2017

Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases

scientific article published on 19 August 2008

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

scientific article

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

scientific article published on 19 July 2012

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.

scientific article

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

scientific article

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

scientific article published on 20 December 2019

Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project

scientific article published on 8 March 2018

Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia

scientific article published on 27 August 2002

Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era

scientific article published on 01 February 2014

Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement.

scientific article

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

scientific article published on 25 June 2015

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

scientific article published on 08 June 2020

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment

scientific article published on 18 September 2015

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

scientific article published on 28 July 2016

Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib

scientific article published on 8 May 2008

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

scientific article published on 12 October 2009

Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia.

scientific article

Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells

scientific article published on 13 July 2011

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism

scientific article

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

scientific article published on 16 July 2012

Plasma cell leukemia occurring in a patient with thrombocythemia treated with hydroxyurea and busulphan.

scientific article published on April 2004

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

scientific article published on 2 October 2017

Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy

scientific article published on 12 October 2012

Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia

scientific article published on 17 September 2008

RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA

scientific article published on 09 April 2020

Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients

scientific article published on 4 February 2009

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

scientific article published on 30 May 2018

Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia

scientific article published on 14 January 2015

Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells

scientific article published in April 2006

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

scientific article published on 11 March 2016

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

scientific article published on 07 January 2021

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients

scientific article published on 16 July 2018

Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy

article

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

scientific article published on 21 November 2020

Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells

scientific article published on May 2007

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

scientific article published on 2 May 2017

The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts

scientific article published on October 2007

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study

scientific article published on 01 August 2007

The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia

scientific article published on 22 October 2009

The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia

scientific article published on 7 November 2015

The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells

scientific article published on 9 March 2010

The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype.

scientific article

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review

scientific article published on 18 September 2019

The significance of early warning in chronic myeloid leukemia.

scientific article

The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status

scientific article

Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice

scientific article published on 12 December 2019

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

scientific article published in February 2009

Two novel NPM1 mutations in a therapy-responder AML patient

scientific article published on 01 September 2010

Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data

scientific article

Unexpected phenotype of a typical NPM1 mutant.

scientific article published on 8 September 2009

WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.

scientific article

What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT?

scientific article published on 21 April 2008

Paulina is supported by:

About Paulina

Help